Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: A randomised, controlled trial

Gut

Volumn 63, Issue 6, 2014, Pages 919-927

  Steenholdt, Casper ^a   Brynskov, Jørn ^a   Thomsen, Ole Østergaard ^a   Munck, Lars Kristian ^b   Fallingborg, Jan ^c   Christensen, Lisbet Ambrosius ^d   Pedersen, Gitte ^e   Kjeldsen, Jens ^f   Jacobsen, Bent Ascanius ^c   Oxholm, Anne Sophie ^g   Kjellberg, Jakob ^g   Bendtzen, Klaus ^h   Ainsworth, Mark Andrew ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b KØGE HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e HVIDOVRE HOSPITAL   (Denmark)

^f ODENSE UNIVERSITY HOSPITAL   (Denmark)

^g Danish Institute for Local and Regional Government Research   (Denmark)

^h Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; C REACTIVE PROTEIN; INFLIXIMAB;

ADULT; AGED; ALGORITHM; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE CONTROL; DRUG BLOOD LEVEL; DRUG DOSE INTENSIFICATION; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; IMMUNOGENICITY; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REGISTER; SINGLE BLIND PROCEDURE; TREATMENT FAILURE; TREATMENT RESPONSE;

COST-EFFECTIVENESS; CROHN'S DISEASE; IBD CLINICAL; INFLIXIMAB; TNF;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; COST-BENEFIT ANALYSIS; CROHN DISEASE; DENMARK; DRUG TOLERANCE; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84899915498     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-305279     Document Type: Article

References (26)

1. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol 2009;104:465-83.
2. Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:644-59, quiz.
3. Dignass A, Van AG, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010;4:28-62.
4. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571-607.
5. D'Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011;106:199-212.
6. Kamm MA, Ng SC, De CP, et al. Practical application of anti-TNF therapy for luminal Crohn's disease. Inflamm Bowel Dis 2011;17:2366-91.
7. Blackhouse G, Assasi N, Xie F, et al. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-alpha drugs for refractory Crohn's disease. J Crohns Colitis 2012;6:77-85.
8. Bendtzen K, Ainsworth M, Steenholdt C, et al. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol 2009;44:774-81.
9. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8. (Pubitemid 36204954)
10. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 2013;108:40-7.
11. Lee LY, Sanderson JD, Irving PM. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis. Eur J Gastroenterol Hepatol 2012;24:1078-85.
12. Chaparro M, Guerra I, Munoz-Linares P, et al. Systematic review: antibodies and anti-TNF-alpha levels in inflammatory bowel disease. Aliment Pharmacol Ther 2012;35:971-86.
13. Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105:1133-9.
14. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011;106:685-98.
15. Ordas I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012;10:1079-87.
16. Velayos FS, Kahn JG, Sandborn WJ, et al. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol 2013;11:654-66.
17. Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006;54:3782-9. (Pubitemid 44955878)
18. Steenholdt C, Bendtzen K, Brynskov J, et al. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 2011;46:310-8.
19. Wang SL, Ohrmund L, Hauenstein S, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods 2012;382:177-88.
20. Feagan BG, Singh S, Lockton S, et al. Novel infliximab (IFX) and antibody-to infliximab (ATI) assays are predictive of disease activity in patients with Crohn's disease. Gastroenterology 2012;142;(Suppl 1):S-565.
21. Casteele N, Cuypers L, Singh S, et al. Antibodies to infliximab can either be persistent or transient: a retrospective case-control study in IBD patients treated with infliximab maintenance therapy. Gastroenterology 2012;142;(Suppl 1):OP563.
22. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009;104:760-7.
23. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000;19:3219-36.
24. Bendtzen K. Anti-TNF-alpha biotherapies: perspectives for evidence-based personalized medicine. Immunotherapy 2012;4:1167-79.
25. Ordas I, Mould DR, Feagan BG, et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012;91:635-46.
26. Nikolaus S, Raedler A, Kuhbacker T, et al. Mechanisms in failure of infliximab for Crohn's disease. Lancet 2000;356:1475-9.